LQDA (Liquidia) Kelajakdagi narxning foydaga nisbati

Liquidia (LQDA) kompaniyasining rasmiy ramzlari

Liquidia Corporation (LQDA) istiqbollari Yutreqsa dori vositasining tijorat muvaffaqiyatiga va patent litigatsiyasi natijalariga bog'liq. Kompaniyaning 12 oylik prognoz qilingan P/E ko'rsatkichi kapital dinamikasini aniq namoyish etadi va ushbu metrika 14.70 darajasida turibdi. Biznesni rivojlantirish dori vositalarini yetkazib berish bo'yicha strategik sheriklikka asoslangan, jabhadagi dadil innovator sifatidagi imidji esa brend texnologiyalarining inqilobiy salohiyatiga ishonadigan investorlarni jalb qilmoqda.

liquidia.com - LQDA Kapitalizatsiyaning kelajakdagi foydaga nisbati (davr: 04.07.2022 - 16.11.2026)

liquidia.com (LQDA) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- joriy narx va aksiyalarning prognoz qilingan qiymati:
- biznesning bozor baholash ko'rsatkichlari:
Fundamental baholash:LQDA Liquidia Technologies
Liquidia Corporation brendining mahsuloti

Forward P/E ko'rsatkichi prognoz qilingan sof foyda orqali kapitalizatsiyaning qoplanishiga bo'lgan bozor kutuvlarini o'lchaydi, bunda ekstremal qiymatlar yo haddan tashqari sotib olingan holatlarni, yoki daromadlarning kritik tarzda qulashini anglatadi. Liquidia Corporation (LQDA) kompaniyasining forward P/E ko'rsatkichini tahlil qilishda, investorlar yuqori R&D xarajatlari va barqaror daromadning yo'qligi dori vositalarining to'liq tijorat ishga tushirilishigacha ushbu koeffitsiyentni vaqtincha oshirib yuborishini hisobga olishlari kerak.

Raqobatdosh kompaniyalar

Kelajakdagi narxning foydaga nisbati haleon.com (HLN)|KVUE (Kenvue Health) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Prognoz qilingan narx-foyda nisbati|LGND: Prognoz qilingan narxning foydaga nisbati|Amneal - Kapitalizatsiyaning kelajakdagi foydaga nisbati|PRGO: Forvard P/E multiplikatori|Alvotech Corp - Kelajakdagi narx-foyda multiplikatori|GLPG (Galapagos N.V.) - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati anipharmaceuticals.com ANIP|Kelajakdagi narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|Forvard P/E multiplikatori ARS Corp SPRY|Theravance Biopharma - Forvard P/E multiplikatori|Forvard narx-foyda multiplikatori Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati SXTC (China SXT Pharmaceuticals)|Forvard P/E multiplikatori EPRX|Forvard P/E multiplikatori bioharvest.com (BHST)|Kelajakdagi narxning foydaga nisbati Invizyne Technologies EXOZ|ORMP: Narxning kelajakdagi foydaga nisbati|ENTX: Prognoz qilingan narxning foydaga nisbati|HYFT: Kelajakdagi narxning foydaga nisbati|ABVC BioPharma Inc. (ABVC) - Kelajakdagi narxning foydaga nisbati|cumberlandpharma.com (CPIX) - Forvard P/E multiplikatori|QNTM (Quantum BioPharma) - Forvard P/E multiplikatori|FGEN: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TELO|Forvard P/E multiplikatori Rani Therapeutics Holdings (RANI)|Forvard P/E multiplikatori SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Prognoz qilingan narx-foyda nisbati|LEXX - Kelajakdagi narxning foydaga nisbati|PULM (Pulmatrix) - Narxning kelajakdagi foydaga nisbati|Pheton Holdings Ltd (PTHL) - Kelajakdagi narxning foydaga nisbati|Aptorum - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati LYRA|Prognoz qilingan narxning foydaga nisbati Impact BioMedical Inc (IBO)|Forvard P/E multiplikatori TNFA|YCBD: Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati PainReform PRFX|altamiratherapeutics.com (CYTO) - Prognoz qilingan narx-foyda nisbati|LIPO: Prognoz qilingan narxning foydaga nisbati|OPTN (optinose.com) - Narxning kelajakdagi foydaga nisbati|PIRS: Forvard P/E multiplikatori|PROC - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|PTPI (Petros Pharma) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati QLI|Forvard P/E multiplikatori SLRN|Kapitalizatsiyaning kelajakdagi foydaga nisbati TFFP